Side-by-side · Research reference
DSIPvsLL-37
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED8/36 cited
BHuman-MechanisticHUMAN-REVIEWED15/35 cited
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
01Mechanism of Action
Parameter
DSIP
LL-37
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Feedback intact?
—
—
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Antibody development
—
—
02Dosage Protocols
Parameter
DSIP
LL-37
Frequency
Once daily, pre-sleep
—
Lower / starter dose
50 mcg pre-sleep
—
Evidence basis
Human-mechanistic + early clinicalSchneider 1986
In vitro, animal models, human observational
Duration
8–12 weeks per cycle
—
Reconstitution
Bacteriostatic water
—
Timing
30–60 min pre-sleep
—
Half-life
Short plasma; CNS effects last hours
—
Endogenous expression
—
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
Exogenous (experimental)
—
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
04Side Effects & Safety
Parameter
DSIP
LL-37
Injection site reaction
Mild irritation
—
Drowsiness
Expected effect (intentional)
—
Vivid dreams
Anecdotally reported
—
Long-term safety
Limited modern RCT data
—
Pregnancy / OB
Avoid
—
Cytotoxicity (high dose)
—
Membrane disruption in host cells at supraphysiological concentrations
Pro-inflammatory signaling
—
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
Theoretical cancer risk
—
Immunomodulatory roles in tumor microenvironment under investigation
Absolute Contraindications
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
LL-37
—Relative Contraindications
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
05Administration Protocol
Parameter
DSIP
LL-37
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
2. Injection site
SQ — abdomen. Rotate sites.
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
3. Timing
30–60 min pre-sleep.
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
—
5. Needle
29–31G insulin syringe.
—